Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Registry Study of Bulevirtide in Chronic Hepatitis D Virus Infection
2022-501901-10-00Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2023
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 4, open-label trial of bulevirtide in hepatitis D (HDV) (2 cohorts), sponsored by Gilead Sciences. Primary endpoint: Exposure-adjusted incidence of liver-related events during bulevirtide treatment. Started Feb 2023; status: completed.
02
Drugs
bulevirtide
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on 2022-501901-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501901-10-00.